Human Cardiac-Derived Adherent Proliferating Cells Reduce Murine Acute Coxsackievirus B3-Induced Myocarditis
Open Access
- 9 December 2011
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (12), e28513
- https://doi.org/10.1371/journal.pone.0028513
Abstract
Under conventional heart failure therapy, inflammatory cardiomyopathy typically has a progressive course, indicating a need for alternative therapeutic strategies to improve long-term outcomes. We recently isolated and identified novel cardiac-derived cells from human cardiac biopsies: cardiac-derived adherent proliferating cells (CAPs). They have similarities with mesenchymal stromal cells, which are known for their anti-apoptotic and immunomodulatory properties. We explored whether CAPs application could be a novel strategy to improve acute Coxsackievirus B3 (CVB3)-induced myocarditis. To evaluate the safety of our approach, we first analyzed the expression of the coxsackie- and adenovirus receptor (CAR) and the co-receptor CD55 on CAPs, which are both required for effective CVB3 infectivity. We could demonstrate that CAPs only minimally express both receptors, which translates to minimal CVB3 copy numbers, and without viral particle release after CVB3 infection. Co-culture of CAPs with CVB3-infected HL-1 cardiomyocytes resulted in a reduction of CVB3-induced HL-1 apoptosis and viral progeny release. In addition, CAPs reduced CD4 and CD8 T cell proliferation. All CAPs-mediated protective effects were nitric oxide- and interleukin-10-dependent and required interferon-γ. In an acute murine model of CVB3-induced myocarditis, application of CAPs led to a decrease of cardiac apoptosis, cardiac CVB3 viral load and improved left ventricular contractility parameters. This was associated with a decline in cardiac mononuclear cell activity, an increase in T regulatory cells and T cell apoptosis, and an increase in left ventricular interleukin-10 and interferon-γ mRNA expression. We conclude that CAPs are a unique type of cardiac-derived cells and promising tools to improve acute CVB3-induced myocarditis.Keywords
This publication has 51 references indexed in Scilit:
- Mesenchymal stem cells improve murine acute coxsackievirus B3-induced myocarditisEuropean Heart Journal, 2010
- Angiotensin-Converting Enzyme Inhibition Prevents the Release of Monocytes From Their Splenic Reservoir in Mice With Myocardial InfarctionCirculation Research, 2010
- A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of Intravenous Adult Human Mesenchymal Stem Cells (Prochymal) After Acute Myocardial InfarctionJournal of the American College of Cardiology, 2009
- Soluble mediators from mesenchymal stem cells suppress T cell proliferation by inducing IL-10Experimental & Molecular Medicine, 2009
- Interferon-γ and NF-κB mediate nitric oxide production by mesenchymal stromal cellsBiochemical and Biophysical Research Communications, 2007
- Transplantation of mesenchymal stem cells attenuates myocardial injury and dysfunction in a rat model of acute myocarditisJournal of Molecular and Cellular Cardiology, 2007
- Multipotent human stromal cells improve cardiac function after myocardial infarction in mice without long-term engraftmentBiochemical and Biophysical Research Communications, 2007
- Interferon γ: a crucial role in the function of induced regulatory T cells in vivoTrends in Immunology, 2006
- Role for Interferon-γ in the Immunomodulatory Activity of Human Bone Marrow Mesenchymal Stem CellsThe International Journal of Cell Cloning, 2005
- Nitric oxide donors inhibit the coxsackievirus B3 proteinases 2A and 3C in vitro, virus production in cells, and signs of myocarditis in virus-infected miceMedical Microbiology and Immunology, 2003